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An anion transporter that links 
urolithiasis and hepatotoxicity
Dawson et al., J Clin Invest 2010; 120: 706–712; doi:10.1172/JCI31474
Sulfate homeostasis results from the balance between diet and 
renal excretion. Most ingested sulfate derives from the metab-
olism of cysteine and methionine, amino acids that contain 
sulfur. All cells require sulfate for normal function, as the addi-
tion of a sulfate moiety to a variety of molecules dramatically 
changes their physicochemical and biological properties. In 
addition, sulfation of exogenous compounds frequently results 
in a decrease in their biological activity, contributing, for exam-
ple, to the detoxification of acetaminophen. Sulfate is filtered at 
the glomerulus and reabsorbed in the proximal tubule, where 
reabsorption works near the maximal rate, and only about 
10% or less of the filtered sulfate appears in the final urine. 
Sulfate tubular reabsorption involves entry through the brush 
border membrane by a Na+-dependent transport system and 
efflux across the basolateral membrane by an anion exchange 
mechanism. Sulfate anion transporter-1 (Sat1) is located in the 
basolateral membrane of the renal proximal tubule and also 
found in the intestine and sinusoidal membrane of hepatocytes, 
where it mediates anion exchange. In addition, Sat1 mediates 
epithelial transport of oxalate, which, unlike sulfate, is a meta-
bolic end product excreted into the urine. To understand the 
function of Sat1, Dawson et al. generated Sat1–/– mice. These 
mice showed disturbed sulfate homeostasis, leading to hypo-
sulfatemia and hypersulfaturia. Interestingly, Sat1–/– mice had 
increased acetaminophen-induced liver toxicity, suggesting that 
hyposulfatemia limits the supply of sulfate for drug metabolism. 
In addition, the mice had abnormal oxalate homeostasis with 
hyperoxalemia, hyperoxaluria, nephrocalcinosis, and calcium 
oxalate urolithiasis (Figure).
This study indicates that Sat1 regulates both oxalate and sul-
fate homeostasis. Additionally, the research provides an animal 
model to study the mechanisms responsible for calcium oxalate 
urolithiasis as well as the mechanisms underlying drug-induced 
hepatotoxicity.
Juan Oliver
Comparative mortality risk  
of anemia management practices  
in incident hemodialysis patients
Brookhart et al., JAMA 2010; 303: 857–864
The guiding of anemia management in patients with kidney 
disease has been confusing and, sometimes, counterintuitive. 
To add to the literature on how risk is caused by high hemo-
globin targets1,2 and the observational data suggesting a rela-
tionship between erythropoiesis-stimulating agent (ESA) dose 
and risk,3,4 Brookhart et al. examined the relationships between 
ESA dose, iron use, hemoglobin levels, and outcomes. The 
authors used data from the United States Renal Data System 
of all patients who began receiving maintenance hemodialysis 
between 1 January 1999 and 31 August 2006, with patients in 
the study cohort randomly split into two subsets. They used 
the first subset to estimate each dialysis unit’s prescription of 
ESAs and iron on the basis of the clinical and demographic 
composition of the unit, and the second subset to describe the 
association between each particular dosing pattern and all-
cause mortality. For patients stratified by level of hematocrit, 
those units with the least aggressive iron dosing patterns had 
the worst outcomes for groups with hematocrit below 33%. 
For groups with hematocrit of 33% and higher, no association 
between dosing pattern of iron and outcomes was seen, except 
among the units with the most aggressive iron dosing patterns 
among patients with hematocrit of 36% or greater. Similar asso-
ciations were seen with respect to ESA dosing. Among patients 
whose hematocrit was less than 30%, no significant association 
between dose and outcomes was demonstrated, except among 
the patients in the highest quintile of dose. Among patients 
with hematocrit levels of 33% or greater, increasing doses were 
associated with worse outcomes in a dose–response pattern.
Although this analysis is based on observational data and 
cannot define cause and effect, one of its strengths lies in the 
large number of included patients, which provides significant 
power to analyze the multiple subgroups presented. Given this 
considerable power, the associations that reflect a dose–response 
relationship or a clear threshold should be given the most con-
fidence. With this in mind, the entirety of these results needs to 
be integrated with the safety hypothesis that dose of ESA may 
confer direct toxicity. The evidence provided in this article sup-
ports this hypothesis, particularly among those patients who are 
at or higher than their hemoglobin goal.
Lynda Szczech
1N Engl J Med 1998; 339: 584–590. 2N Engl J Med 2006; 355: 2085–2098. 3Kidney Int 
2008; 74: 791–798. 4Am J Kidney Dis 2004; 44: 866–876.
Urolithiasis in Sat1–/– mice. Kidney sections showing infiltration of 
leukocytes (arrow) around the renal cortical vessels in Sat1–/– mice but not 
in Sat1+/+ mice (a and b). Kidneys of Sat1–/– mice frequently had calcium 
oxalate stones, shown as dark staining (c and d).
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Urea-induced ROS generation 
causes insulin resistance in mice 
with chronic renal failure
D’Apolito et al., J Clin Invest 2010; 120: 203–213; doi:10.1172/JCI37672
In 1972, Johnson et al. found that patients with far-advanced 
renal failure well tolerated blood urea concentration maintained 
by the addition of urea to the dialysate solution.1 Thirty years 
later, the HEMO study showed that increasing the urea reduc-
tion rate from 66% to 75% did not alter survival in patients with 
an increased dialysis dose. Nonphysiological concentrations of 
urea have been reported to increase levels of reactive oxygen 
species (ROS) and the oxidative stress marker 8-oxoguanine in 
cultured IMCD3 cells.2 Previously, D’Apolito et al. demonstrated 
that ROS increases intracellular protein modification by O-linked 
β-N-acetylglucosamine (O-GlcNAc), and others have shown that 
increased modification of insulin signaling molecules by O-Glc-
NAc reduces insulin signal transduction. Because both oxidative 
stress and insulin resistance have been observed in patients with 
end-stage renal disease (ESRD), D’Apolito et al. sought to deter-
mine the role of urea in these phenotypes. Treatment of 3T3-L1 
adipocytes with urea at disease-relevant concentrations induced 
ROS production, caused insulin resistance, increased expression 
of the adipokines retinol-binding protein 4 (RBP4) and resistin, 
and increased O-GlcNAc-modified insulin signaling molecules. 
Investigation of a mouse model of surgically induced renal fail-
ure (uremic mice) revealed increased ROS production, modifica-
tion of insulin signaling molecules by O-GlcNAc, and increased 
expression of RBP4 and resistin in visceral adipose tissue. Uremic 
mice also displayed insulin resistance and glucose intolerance, and 
treatment with an antioxidant superoxide dismutase (SOD)/cata-
lase mimetic normalized these defects. The SOD/catalase mimetic 
treatment also prevented the development of insulin resistance in 
normal mice after urea infusion (Figure).
These data suggest that therapeutic targeting of urea-induced 
ROS may help reduce the high morbidity and mortality caused 
by ESRD.
Marc De Broe
1Mayo Clin Proc 1972; 47: 21–29. 2Proc Natl Acad Sci USA 2004; 101: 9491–9496.
Interaction of the parathyroid 
hormone and TGF-β receptors  
in bone remodeling
Qiu et al., Nat Cell Biol 2010; 12: 224–234; doi:10.1038/ncb2022
Like many G protein-coupled receptors, the parathyroid hormone 
receptor (PTHR) becomes internalized by endocytosis after it binds 
to its ligand, because of phosphorylation of its cytoplasmic tail. 
This process makes the receptor unavailable for binding to par-
athyroid hormone (PTH) and, hence, acts to shut off the signal-
ing cascade. PTH activates osteoclasts, causing them to release a 
number of matrix components, including transforming growth 
factor-β (TGF-β). Evidence shows that PTH and TGF-β act in a 
similar pathway to prevent apoptosis in osteoblasts, and there are 
likely other combined effects. Recently, Qiu et al. investigated the 
mechanism by which TGF-β affects PTHR. They found that PTH 
caused recruitment of the TGF-β type II receptor (TβRII) to a patch 
of membrane that contained PTHR. TβRII is a serine kinase, and 
this recruitment resulted in direct phosphorylation of the cytoplas-
mic domain of PTHR, thereby causing endocytosis. Therefore, the 
endocytosis of PTHR is associated with endocytosis of TβRII as 
well. The two receptors existed in a complex that combined with 
the internalization machinery of vesicles. This effect was specific 
to TβRII, since PTH did not induce endocytosis of the insulin-like 
growth factor receptor. These studies had a functional consequence 
in that the addition of PTH caused attenuation of the transcrip-
tional activity induced by TGF-β receptors. Blockade of endocy-
tosis prevented this attenuation. Similarly, expression of TβRII 
attenuated the effect of PTH in the production of cyclic adenosine 
monophosphate. Hence, the two receptors interacted to cause endo-
cytosis, reducing the activity of both receptors. The authors then 
studied osteoblasts obtained from mice with knockout of TβRII 
and found that these osteoblasts had a high level of expression of 
PTHR. Examination of bone from these mice showed enhanced 
osteoblast function, that is, increased bone mass and bone mineral 
density, with increased production of porous trabecular bone and 
reduced formation and thickness of cortical bone. Injection of a 
PTH antagonist corrected these abnormalities, while PTHR knock-
out mice had increased production of porous trabecular bone and 
reduced formation and thickness of cortical bone.
These studies provide a new model whereby bone remodeling is 
seen as the coordinated interaction between two signaling systems 
that together control mineralization of bone. Future studies will be 
needed to see whether these studies will open new therapeutic ave-
nues for the treatment of osteoporosis or renal osteodystrophy.
Qais Al-Awqati
Treatment of uremic mice with a SOD/catalase mimetic normalizes insulin 
resistance and glucose intolerance. Treated uremic mice and treated 
controls received mimetic tetrakis (4-benzoic acid) porphyrin (MnTBAP) 
intraperitoneally (i.p.) for 2 weeks. (a) Insulin tolerance test. Mice were 
injected i.p. with insulin (0.75 U/kg), and blood glucose was measured at 
0, 30, and 60 minutes. (b) Intraperitoneal glucose tolerance test (IPGTT). 
Mice were injected i.p. with glucose (1 mg/g body weight), and blood 
glucose was measured at 0, 15, 30, 60, and 120 minutes. (c) Insulin 
resistance in uremic mice. Insulin values from the IPGTT animals shown in 
b were determined by enzyme-linked immunosorbent assay. (d) Glucose 
intolerance in uremic mice. Glucose values from b at 0 and 120 minutes. All 
results represent mean ± s.e.m. of seven animals per group.
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